Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

BACKGROUND: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jernström, Sandra, Hongisto, Vesa, Leivonen, Suvi-Katri, Due, Eldri Undlien, Tadele, Dagim Shiferaw, Edgren, Henrik, Kallioniemi, Olli, Perälä, Merja, Mælandsmo, Gunhild Mari, Sahlberg, Kristine Kleivi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367762/
https://www.ncbi.nlm.nih.gov/pubmed/28356768
http://dx.doi.org/10.2147/BCTT.S115600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367762/
https://www.ncbi.nlm.nih.gov/pubmed/28356768
http://dx.doi.org/10.2147/BCTT.S115600

Ejemplares similares